Krystal Biotech, Inc (KRYS)

Etorro trading 970x250
Krystal Biotech, Inc (KRYS) Logo

About Krystal Biotech, Inc

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and acne scars; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx for other rare lung disease. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania. Address: 2100 Wharton Street, Pittsburgh, PA, United States, 15203

Krystal Biotech, Inc News and around…

Latest news about Krystal Biotech, Inc (KRYS) common stock and company :

Investors Bag KRYS 8.2% Lower Than Its Secondary Stock Offering
02 Dec, 2021 FinancialContent

Looking back to 2 days ago, Krystal Biotech Inc (KRYS) priced a 2,666,667 share secondary stock offering at $75.00 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time..

Why Krystal Biotech Stock Is Retreating Today
01 Dec, 2021 FinancialContent

A public offering is weighing on the biotech's shares today.

Krystal Biotech Announces Pricing of $200 Million Public Offering of Common Stock
01 Dec, 2021 Yahoo! Finance

PITTSBURGH, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has priced the previously announced underwritten public offering of 2,666,667 shares of its common stock, at a public offering price of $75.00 per share. The Company and certain selling stockholders granted the underwriters a 30-day option to purchase up to an additional 400,000 shares of the Company’s common stock o

Company News for Nov 30, 2021
30 Nov, 2021 Yahoo! Finance

Companies in the news are: KRYS, ADGI, NRXP, HTZ

The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout
30 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Cumberland Gets FDA Approval ...

50 Biggest Movers From Yesterday
30 Nov, 2021 FinancialContent

Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares surged 121.7% to close at $88.24 on Monday after the company announced ...

4 Top Biotech Stocks To Watch Now
29 Nov, 2021 FinancialContent
12 Health Care Stocks Moving In Monday's After-Market Session
29 Nov, 2021 FinancialContent

Gainers Cumberland (NASDAQ:CPIX) shares moved upwards by 97.27% to $4.34 during Monday's after-market session. At the close, ...

First Gene Therapy for Skin, From Krystal, Heals Wounded Kids
29 Nov, 2021 Yahoo! Finance

Shares of Krystal were up 120% in Monday trading on the company's report of initial data from the pivotal trial of its Vyjuvek treatment.

Krystal Biotech Announces Proposed $200 Million Public Offering of Common Stock
29 Nov, 2021 Yahoo! Finance

PITTSBURGH, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has commenced a $200 million underwritten public offering of its common stock. The Company and certain selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional $30 million of the shares of the Company’s common stock offered in the public offering. The offering is subject t

Mid-Afternoon Market Update: Dow Jumps 300 Points; Krystal Biotech Shares Spike Higher
29 Nov, 2021 FinancialContent

Toward the end of trading Monday, the Dow traded up 0.87% to 35,204.42 while the NASDAQ climbed 1.96% to 15,795.08. The S&P also ...

12 Health Care Stocks Moving In Monday's Intraday Session
29 Nov, 2021 FinancialContent

Gainers Krystal Biotech (NASDAQ:KRYS) shares moved upwards by 118.21% to $86.87 during Monday's regular session. ...

Stocks Rise as "Fear Gauge" Cools Off
29 Nov, 2021 FinancialContent

The Dow Jones Industrial Average and Nasdaq Composite are both up triple digits midday, paring some of their losses from Friday's massive selloff.

Mid-Day Market Update: Crude Oil Rises 4%; Fennec Pharmaceuticals Shares Slide
29 Nov, 2021 FinancialContent

Midway through trading Monday, the Dow traded up 0.30% to 35,005.10 while the NASDAQ climbed 1.39% to 15,707.48. The S&P also rose, ...

33 Stocks Moving In Monday's Mid-Day Session
29 Nov, 2021 FinancialContent

Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares jumped 116.4% to $86.13 after the company announced positive topline results ...

KRYS Stock Alert: The Study Results That Have Krystal Biotech Rocketing 118% Today
29 Nov, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Krystal Biotech (KRYS) stock is rising higher on Monday thanks to positive results from a recent Phase 3 clinical trial of VYJUVEK. The post KRYS Stock Alert: The Study Results That Have Krystal Biotech Rocketing 118% Today appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

Mid-Morning Market Update: Markets Open Higher; Li Auto Sales Top Views
29 Nov, 2021 FinancialContent

Following the market opening Monday, the Dow traded up 0.22% to 34,977.01 while the NASDAQ climbed 1.53% to 15,727.94. The S&P also ...

5 Top Stock Gainers for Monday: Zscaler, Krystal Biotech, Adagio
29 Nov, 2021 Yahoo! Finance

Zscaler, Krystal Biotech, Adagio Therapeutics, Moderna and Royal Caribbean are five top stock gainers for Monday.

12 Health Care Stocks Moving In Monday's Pre-Market Session
29 Nov, 2021 FinancialContent

Gainers Krystal Biotech (NASDAQ:KRYS) shares moved upwards by 120.29% to $87.7 during Monday's pre-market session. ...

Krystal Biotech Shares More Than Double During Premarket Monday: What Investors Need To Know
29 Nov, 2021 FinancialContent

Krystal Biotech Inc(NASDAQ: KRYS) hasannounced positive topline resultsfrom the GEM-3 Phase 3 trial of investigational ...

Krystal Biotech Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK™ in Patients with Dystrophic Epidermolysis Bullosa
29 Nov, 2021 Yahoo! Finance

• Pivotal GEM-3 trial met its primary endpoint of complete wound healing at six-month timepoints, and its secondary endpoint of complete wound healing at three-month timepoints VYJUVEKTM was well tolerated, with no drug-related serious adverse events or discontinuations Biologics License Application (BLA) on track to be submitted to U.S. Food and Drug Administration (FDA) in 1H22Conference call to discuss results scheduled for today, Monday, November 29, 2021 at 8:00 a.m. EST PITTSBURGH, Nov. 29

Krystal Biotech Shares More Than Double After Positive VYJUVEK Trial Results
29 Nov, 2021 Yahoo! Finance

By Sam Boughedda

61 Biggest Movers From Yesterday
23 Nov, 2021 FinancialContent

Gainers Longeveron Inc. (NASDAQ: LGVN) shares surged 181.2% to settle at $28.20 on Monday on continued upward momentum after the ...

40 Stocks Moving In Monday's Mid-Day Session
22 Nov, 2021 FinancialContent

Gainers iSpecimen Inc. (NASDAQ: ISPC) shares climbed 126.5% to $11.12 after the company announced it has been contracted to ...

Jeune Aesthetics to Present Pre-clinical Data Highlighting the Potential of KB303 in Elastin Production at the ASDS 2021 Virtual Meeting
19 Nov, 2021 Yahoo! Finance

Pre-clincal program evaluated proper formation and deposition of elastic fibers into the skin extracellular matrix in miceKB303 holds potential to be the first-ever directed approach to increase production of elastin in the skin PITTSBURGH, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc., a wholly-owned subsidiary of Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS) today announced the presentation of preclinical data supporting the ongoing development of KB303, an innovative, investiga

Noteworthy Tuesday Option Activity: KRYS, DKNG, RXT
16 Nov, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Krystal Biotech Inc (KRYS), where a total volume of 2,040 contracts has been traded thus far today, a contract volume which is representative of approximately 204,000 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 110.1% of KRYS's average daily trading volume over the past month, of 185,295 shares..

Notable Monday Option Activity: KRYS, MARA, SEAS
08 Nov, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Krystal Biotech Inc (KRYS), where a total volume of 2,462 contracts has been traded thus far today, a contract volume which is representative of approximately 246,200 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 154.2% of KRYS's average daily trading volume over the past month, of 159,680 shares..

Krystal's new Pittsburgh gene therapy center to be operational in 2022
08 Nov, 2021 Yahoo! Finance

It announced in 2019 that it would expand into a second center for gene therapy production, for a 150,000-square-foot building that it's calling ASTRA.

Krystal Biotech Reports Third Quarter 2021 Financial Results and Provides Update on Operational Progress
08 Nov, 2021 Yahoo! Finance

– Top-line results from the pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (DEB) on track for 4Q21 – Enrollment in Phase 1 proof-of-concept study (PEARL-1 study) to treat aesthetic skin conditions is complete – Strong balance sheet with September 30, 2021 cash, cash equivalents, and investments of $362.3 million PITTSBURGH, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today reporte

Gene Therapy Is a Huge Opportunity. It Pays to be Patient.
06 Nov, 2021 Yahoo! Finance

Biotechs and big pharma companies are targeting diabetes, cardiovascular problems, and even wrinkles. This is one opportunity where it pays to be patient.

Krystal Biotech, Inc (KRYS) is a NASDAQ Common Stock listed in , ,

970x250